Abstract
Diabetes is a prevalent disease which effects over 150 million people worldwide and there is a great medical need for new therapeutic agents to treat it. Inhibition of protein tyrosine phosphatase 1B (PTP1B) has emerged as a highly validated, attractive target for treatment of not only diabetes but also obesity. Discovery of small-molecule inhibitors has been pursued extensively in both academia and industry and a number of very potent and selective inhibitors have been identified. With X-ray crystallography, the binding interactions of several classes of inhibitors have been elucidated. This has resulted in significant progress in understanding important interactions between inhibitors and specific residues of PTP1B, which could help the design of future inhibitors. However, since the active site of PTP1B that most of these inhibitors bind to is highly hydrophilic, it remains a challenge to identify inhibitors with both excellent in vitro potency and drug-like physiochemical properties which would lead to good in vivo activities.
Keywords: protein phosphatase, protein tyrosine phosphatase 1b, ptp1b, ptp1b inhibitors, diabetes, anti-hyperglycemia, insulin resistance, obesity
Current Pharmaceutical Design
Title: Inhibition of Protein Tyrosine Phosphatase 1B as a Potential Treatment of Diabetes and Obesity
Volume: 10 Issue: 28
Author(s): Zhonghua Pei, Gang Liu, Thomas H. Lubben and Bruce G. Szczepankiewicz
Affiliation:
Keywords: protein phosphatase, protein tyrosine phosphatase 1b, ptp1b, ptp1b inhibitors, diabetes, anti-hyperglycemia, insulin resistance, obesity
Abstract: Diabetes is a prevalent disease which effects over 150 million people worldwide and there is a great medical need for new therapeutic agents to treat it. Inhibition of protein tyrosine phosphatase 1B (PTP1B) has emerged as a highly validated, attractive target for treatment of not only diabetes but also obesity. Discovery of small-molecule inhibitors has been pursued extensively in both academia and industry and a number of very potent and selective inhibitors have been identified. With X-ray crystallography, the binding interactions of several classes of inhibitors have been elucidated. This has resulted in significant progress in understanding important interactions between inhibitors and specific residues of PTP1B, which could help the design of future inhibitors. However, since the active site of PTP1B that most of these inhibitors bind to is highly hydrophilic, it remains a challenge to identify inhibitors with both excellent in vitro potency and drug-like physiochemical properties which would lead to good in vivo activities.
Export Options
About this article
Cite this article as:
Pei Zhonghua, Liu Gang, Lubben H. Thomas and Szczepankiewicz G. Bruce, Inhibition of Protein Tyrosine Phosphatase 1B as a Potential Treatment of Diabetes and Obesity, Current Pharmaceutical Design 2004; 10 (28) . https://dx.doi.org/10.2174/1381612043382954
DOI https://dx.doi.org/10.2174/1381612043382954 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews Charge Deficient Analogues of the Natural Polyamines
Current Pharmaceutical Design PDE-5 Inhibitors: Clinical Points
Current Drug Targets Bone Disruption and Environmental Pollutants
Endocrine, Metabolic & Immune Disorders - Drug Targets Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy
Current Pharmaceutical Design FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders?
Current Diabetes Reviews Promising Anti-stroke Signature of Voglibose: Investigation through In- Silico Molecular Docking and Virtual Screening in In-Vivo Animal Studies
Current Gene Therapy Retinal Neurodegeneration in the Course of Diabetes-Pathogenesis and Clinical Perspective
Current Neuropharmacology Physiological Effect and Therapeutic Application of Alpha Lipoic Acid
Current Medicinal Chemistry Weight Loss Following Roux-en-Y Gastric Bypass Surgery: A Systematic Review of Psychosocial Predictors
Current Psychiatry Reviews Editorial (thematic Issue: Functional Performance of L-Carnosine (β-Alanyl-L-Histidine) and Related Imidazole-Containing Dipeptides. Design and Modern Applications of Drug Delivery Systems (Nanosuspensions of Nanosize Materials, Mucoadhesive Drug Delivery Systems, Formulations of Transdermal Patches for Controlled Drug Delivery)
Recent Patents on Drug Delivery & Formulation GSK-3 Inhibitors: Recent Developments and Therapeutic Potential
Current Signal Transduction Therapy Editorial [Hot Topic: Inflammation in Atherosclerosis: Current Therapeutic Approaches (Executive Guest Editor: Dimitris Tousoulis)]
Current Pharmaceutical Design Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Current Cancer Drug Targets Potential Role of Endothelin in Early Vascular Aging
Current Hypertension Reviews The Economic Costs for the Control of Cardiovascular Risk: An Overview
Current Pharmaceutical Design Recent Advances in the Development of Pharmaceutical Agents for Metabolic Disorders: A Computational Perspective
Current Medicinal Chemistry Phenomenology and Neurobiology of Childhood Onset Schizophrenia
Current Psychiatry Reviews Antihyperglycemic Effect of the Aqueous Extract of <i>Foeniculum vulgare</i> in Normal and Streptozotocin-induced Diabetic Rats
Cardiovascular & Hematological Disorders-Drug Targets Nailfold Capillaroscopy Within and Beyond the Scope of Connective Tissue Diseases
Current Rheumatology Reviews